An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53

被引:10
作者
Huang, Yongmi [1 ]
Jiao, Zhihao [1 ]
Fu, Yuqing [1 ]
Hou, Yue [1 ]
Sun, Jinxiao [1 ]
Hu, Feiran [1 ]
Yu, Shangzhe [1 ]
Gong, Kexin [1 ]
Liu, Yiru [1 ]
Zhao, Guisen [1 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Sch Pharmaceut Sci, Dept Med Chem,Key Lab Chem Biol,Minist Educ, Jinan 250012, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Gain of function (GOF); Tumor protein 53 (TP53); p53; Tumor suppressor; Clinical trial; GAIN-OF-FUNCTION; IN-VITRO; MDM2; CP-31398; TETRAMERIZATION; INACTIVATION; PERSPECTIVES; DEGRADATION; ANTAGONISTS; ACTIVATION;
D O I
10.1016/j.ejmech.2024.116121
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
TP53, also known as the "guardian of the genome," is an important tumor suppressor gene. It is encoded by the human genome and is associated with the development of diverse cancers. The p53 protein, encoded by TP53, functions in the cell to monitor DNA damage and prompts the cell to respond appropriately. When DNA is damaged, p53 halts the cell cycle, allowing cells to enter the repair state. If the repair is ineffective, p53 induces cell death via apoptosis. This prevents DNA damage transmission during cell division and reduces cancer risk. However, the p53 gene mutation compromises its function. This leads to the inability of cells to respond properly to DNA damage, which may result in cancer development. Mutations in p53 are widespread in diverse cancers, especially highly prevalent cancers, including breast, colon, and lung cancers. Despite the association between p53 mutations and cancer, researchers have discovered drugs and treatments that may reactivate mutated p53 function. Therefore, p53 remains an important area of research in cancer treatment and holds promise as a new direction for cancer therapy. In summary, TP53 is a vital tumor suppressor gene responsible for monitoring DNA damage and prompting cells to respond appropriately. This article summarizes drugs related to p53 and diverse strategies for discovering drugs that act on either wide or mutant p53. Herein, p53 is categorized into two types: wild and mutant type. Drugs are also classified according to diverse treatment strategies, enabling readers to differentiate between the two types of p53 and aiding in selecting the appropriate research direction. Additionally, this review offers a valuable reference for drug design.
引用
收藏
页数:13
相关论文
共 80 条
  • [1] Amaral JD, 2010, DISCOV MED, V9, P145
  • [2] [Anonymous], 2022, Glimmers of Hope for Targeting P53, P12
  • [3] Gain-of-function mutant p53: history and speculation
    Bargonetti, Jill
    Prives, Carol
    [J]. JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (07) : 605 - 609
  • [4] A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C
    Bauer, Matthias R.
    Jones, Rhiannon N.
    Tareque, Raysa K.
    Springett, Bradley
    Dingler, Felix A.
    Verduci, Lorena
    Patel, Ketan J.
    Fersht, Alan R.
    Joerger, Andreas C.
    Spencer, John
    [J]. FUTURE MEDICINAL CHEMISTRY, 2019, 11 (19) : 2491 - 2504
  • [5] APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
    Birsen, Rudy
    Larrue, Clement
    Decroocq, Justine
    Johnson, Natacha
    Guiraud, Nathan
    Gotanegre, Mathilde
    Cantero-Aguilar, Lilia
    Grignano, Eric
    Huynh, Tony
    Fontenay, Michaela
    Kosmider, Olivier
    Mayeux, Patrick
    Chapuis, Nicolas
    Sarry, Jean Emmanuel
    Tamburini, Jerome
    Bouscary, Didier
    [J]. HAEMATOLOGICA, 2022, 107 (02) : 403 - 416
  • [6] p53, cancer and the immune response
    Blagih, Julianne
    Buck, Michael D.
    Vousden, Karen H.
    [J]. JOURNAL OF CELL SCIENCE, 2020, 133 (05)
  • [7] Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
    Boeckler, Frank M.
    Joerger, Andreas C.
    Jaggi, Gaurav
    Rutherford, Trevor J.
    Veprintsev, Dmitry B.
    Fersht, Alan R.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (30) : 10360 - 10365
  • [8] TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
    Bouaoun, Liacine
    Sonkin, Dmitriy
    Ardin, Maude
    Hollstein, Monica
    Byrnes, Graham
    Zavadil, Jiri
    Olivier, Magali
    [J]. HUMAN MUTATION, 2016, 37 (09) : 865 - 876
  • [9] BUESORAMOS CE, 1993, BLOOD, V82, P2617
  • [10] Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
    Chen, Shuo
    Wu, Jia-Le
    Liang, Ying
    Tang, Yi-Gang
    Song, Hua-Xin
    Wu, Li-Li
    Xing, Yang-Fei
    Yan, Ni
    Li, Yun-Tong
    Wang, Zheng-Yuan
    Xiao, Shu-Jun
    Lu, Xin
    Chen, Sai-Juan
    Lu, Min
    [J]. CANCER CELL, 2021, 39 (02) : 225 - +